Median age (range) | 37 (26–62) |
M/F ratio | 2:11 |
CD/UC | 8:5 |
Number of patients on concurrent immunosuppression | 7 |
Median (range) duration of infliximab in months prior to DILE | 14 (1–52) |
Median (range) number of infliximab infusions prior to DILE | 10 (2–30) |
Recurrence of lupus like reaction after exposure to second anti-TNF agent | 25% |
Median (range) period of treatment with second anti-TNF agent | 5 months (2–6) |